SourceBio International plc
(“SourceBio”, the ”Company” or ”the Group”)
Launch of Group 2021 SAYE Scheme
Grant of 2021 SAYE Options
SourceBio International plc (AIM: SBI), a leading international provider of integrated state-of-the-art laboratory services and products, announces the grant of options as part of its HMRC approved 2021 Save As You Earn Scheme (“2021 SAYE scheme”).
The 2021 SAYE scheme was made available to all eligible UK employees having completed three months of service, giving them the opportunity to participate in the future growth of the Group via share option arrangements. The options have an exercise price of 132.5 pence, being the closing price on 12 October 2021, the trading day before the invitation to participate was made. A total of 68 employees of the Group, representing approximately 23% of the eligible population, elected to participate in the 2021 SAYE Scheme. A total of 145,984 options over ordinary shares of 0.15 pence each in the capital of the Company (“2021 SAYE Options”) have been granted, representing approximately 0.2% of the current issued share capital of 74,183,038 shares.
The 2021 SAYE Options have a contract start date of 1 December 2021 and the scheme will run for a period of three years. Subject to the rules of the 2021 SAYE Scheme, participants will be able to exercise their 2021 SAYE Options within six months commencing from 1 December 2024.
Contacts:
| SourceBio International plc | ||
|
Jay LeCoque, Executive Chairman |
Via Walbrook PR |
|
| Tony Ratcliffe, Chief Financial Officer | ||
| Liberum (Nominated Adviser and Broker) |
Tel: 020 3100 2000 |
|
| Bidhi Bhoma / Richard Lindley | ||
| Walbrook PR Limited |
Tel: 020 7933 8780 or sourcebio@walbrookpr.com |
|
| Paul McManus / Sam Allen |
Mob: 07980 541 893 / 07502 558 258 |
|
About SourceBio International plc www.sourcebiointernational.com
SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas:
- Infectious Disease Testing – a range of COVID-19 testing services for commercial enterprises, private healthcare groups, NHS and the DHSC. Utilising multiple technologies, SourceBio offers screening, gold standard RT-PCR, whole genome sequencing and lateral flow COVID-19 testing solutions and operates under ISO 15189 accreditation required by the DHSC. SourceBio also provides employee testing solutions to industry, and direct to consumer home test kits (including ”Fit to Fly”, ”Test to Release” and ”Day 2 & Day 8 International Travel” approved tests).
- Healthcare Diagnostics – histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.
- Genomics – DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.
- Stability Storage – shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA.
More details on Group operations can be found here: www.sourcebioscience.com.
SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.
